

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)



(10) International Publication Number
WO 2023/215482 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) A61K 31/4725 (2006.01)
C07D 451/06 (2006.01) A61P 35/00 (2006.01)
C07D 487/08 (2006.01) A61K 47/50 (2017.01)

(21) International Application Number:

PCT/US2023/021010

(22) International Filing Date:

04 May 2023 (04.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/339,253	06 May 2022 (06.05.2022)	US
63/398,783	17 August 2022 (17.08.2022)	US
63/429,862	02 December 2022 (02.12.2022)	US
63/449,756	03 March 2023 (03.03.2023)	US
63/454,545	24 March 2023 (24.03.2023)	US
63/457,997	07 April 2023 (07.04.2023)	US



(71) Applicant: **TREELINE BIOSCIENCES, INC.** [US/US];
677 Washington Blvd., Suite 525, Stamford, Connecticut
06901 (US).

(72) Inventors: **HORN, Evan J.**; 11180 Roselle Street, Suite A,
San Diego, California 92121 (US). **HANSEN, Joshua D.**;
11180 Roselle Street, Suite A, San Diego, California 92121
(US). **ALEXANDER, Matthew D.**; 11180 Roselle Street,
Suite A, San Diego, California 92121 (US). **HUANG, Fei**;
11180 Roselle Street, Suite A, San Diego, California 92121
(US). **NAGY, Mark A.**; 11180 Roselle Street, Suite A, San
Diego, California 92121 (US).

(74) Agent: **KENDALL, John T.** et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-X_L DEGRADERS



(57) Abstract: This disclosure provides compounds of Formula (I) (e.g., (I-A) (e.g., (I-A-1), (I-A-2), or (I-A-3)), (I-B) (e.g., (I-B-1), (I-B-2), or (I-B-3)), (I-C), (I-D), (I-E) (e.g., (I-E-1), (I-E-2), or (I-E-3)), (I-Ea) (e.g., (I-Ea-1), (I-Ea-2), or (I-Ea-3)), (I-Eb) (e.g., (I-Eb-1), (I-Eb-2), or (I-Eb-3)), (I-F) (e.g., (I-F-1), (I-F-2), or (I-F-3)), (I-G), (I-Ga), (I-H) (e.g., (I-H-1), (I-H-2), or (I-H-3))) or Formula (II) (e.g., (II-a)), or a pharmaceutically acceptable salt thereof that induce degradation of a BCL-X_L protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein as well as methods of using and making the same.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*